Review
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Apr 15, 2014; 5(2): 160-164
Published online Apr 15, 2014. doi: 10.4239/wjd.v5.i2.160
Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives
Gijs WD Landman, Henk JG Bilo, Sebastiaan T Houweling, Nanne Kleefstra
Gijs WD Landman, Henk JG Bilo, Sebastiaan T Houweling, Nanne Kleefstra, Diabetes Centre, Isala, 8000 GK Zwolle, The Netherlands
Henk JG Bilo, Department of Internal Medicine, University Medical Center, 9700 RB Groningen, The Netherlands
Sebastiaan T Houweling, Department of General Practice, University Medical Centre, 9700 RB Groningen, The Netherlands
Author contributions: Landman GWD and Kleefstra N Performed literature search; Landman GWD and Kleefstra N analyzed literature search results; Landman GWD, Bilo HJG, Houweling ST and Kleefstra N wrote the paper.
Correspondence to: Gijs WD Landman, MD, PhD, Diabetes Centre, Isala, P.O. box 10400, 8000 GK Zwolle, The Netherlands. g.w.d.landman@isala.nl
Telephone: +31-38-4242518 Fax: +31-38-4247694
Received: December 11, 2013
Revised: January 23, 2014
Accepted: March 13, 2014
Published online: April 15, 2014
Abstract

Chromium is considered to have positive effects on insulin sensitivity and is marketed as an adjunctive therapy for inducing glucose tolerance in cases of insulin resistance (“the glucose tolerance factor”). Case reports on patients who received prolonged parenteral nutrition indeed showed that the absence of trivalent chromium caused insulin resistance and diabetes. However, whether patients with type 2 diabetes can develop a clinically relevant chromium deficiency is unclear. This review summarizes the available evidence regarding the potential effectiveness of chromium supplementation on glycemic control (Hemoglobin A1c levels) in patients with type 2 diabetes. No studies investigating the long-term safety of chromium in humans were found. All clinical trials that have been performed had a relative short follow-up period. None of the trials investigated whether the patients had risk factors for chromium deficiency. The evidence from randomized trials in patients with type 2 diabetes demonstrated that chromium supplementation does not effectively improve glycemic control. The meta-analyses showed that chromium supplementation did not improve fasting plasma glucose levels. Moreover, there were no clinically relevant chromium effects on body weight in individuals with or without diabetes. Future studies should focus on reliable methods to estimate chromium status to identify patients at risk for pathological alterations in their metabolism associated with chromium deficiency. Given the present data, there is no evidence that supports advising patients with type 2 diabetes to take chromium supplements.

Keywords: Chromium, Type 2 diabetes mellitus, Insulin resistance, Therapy, Supplements

Core tip: In some patients who received prolonged parenteral nutrition, absence of trivalent chromium caused insulin resistance and diabetes and supplementation with trivalent chromium “cleared” this metabolic disease. The question is, whether chromium deficiency is a relevant factor in the cause of type 2 diabetes in general and whether supplementation with trivalent chromium can have beneficial effects in type 2 diabetes. Unfortunately, no reliable methods to estimate chromium status exists and according to current evidence, chromium does not improve glycemic control in patients with type 2 diabetes and patients should be advised not to take chromium supplements.